Finward Bancorp Purchases New Position in Pfizer Inc. (NYSE:PFE)

Finward Bancorp acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 13,253 shares of the biopharmaceutical company’s stock, valued at approximately $352,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Pfizer during the fourth quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Pfizer during the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. increased its holdings in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after purchasing an additional 5,153,257 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. UBS Group lowered their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Stock Up 1.5 %

PFE opened at $22.45 on Wednesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a market capitalization of $127.30 billion, a P/E ratio of 15.92, a PEG ratio of 0.64 and a beta of 0.67. The company’s 50-day moving average is $25.09 and its 200 day moving average is $26.31. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 earnings per share. Pfizer’s revenue was up 24.7% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.